SCHEMBL19425915

SCHEMBL19425915

CCCCCOc1cccc2c1C(=O)C=C(C)C2=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.62
▸ ALDH1A1 P00352 3/20 0.62
▸ LMNA P02545 3/20 0.62
▸ APAF1 O14727 1/20 0.62
▸ MITF O75030 1/20 0.62
▸ HTT P42858 1/20 0.62
▸ TP53 P04637 3/20 0.50
▸ MEN1 O00255 3/20 0.50
▸ CYP3A4 P08684 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ CYP1A2 P05177 2/20 0.50
▸ HSPD1 P10809 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ MAPK1 P28482 2/20 0.50
▸ CDC25A P30304 2/20 0.50
▸ CDC25B P30305 2/20 0.50
▸ BLM P54132 2/20 0.50
▸ HSPE1 P61604 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ TST Q16762 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21076346 0.96 ALDH1A1 (0.64) MAPTALDH1A1LMNAAPAF1MITF
SCHEMBL17594409 0.88 ALDH1A1 (0.61) MAPTALDH1A1LMNAAPAF1MITF
SCHEMBL19409312 0.86 ALDH1A1 (0.62) MAPTALDH1A1LMNAAPAF1MITF
SCHEMBL9629398 0.85 MAPT (0.69) MAPTALDH1A1LMNAAPAF1MITF
SCHEMBL918577 0.82 KCNA3 (0.63) MAPTLMNAMEN1CYP3A4KMT2A
SCHEMBL16076555 0.79 KCNA3 (0.62) MAPTALDH1A1MEN1KMT2ACYP1A2
SCHEMBL20678449 0.78 KCNA3 (0.71) MAPTLMNAMEN1CYP3A4KMT2A
SCHEMBL27604497 0.78 KCNA3 (0.71) MAPTLMNAMEN1CYP3A4KMT2A
SCHEMBL9627716 0.77 ALDH1A1 (1.00) MAPTALDH1A1LMNAAPAF1MITF
SCHEMBL9017760 0.77 ELANE (0.67) CYP1A2KCNA3ELANECYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10577315-B2 Compositions and methods for treatment of prostate carcinoma PELLFICURE PHARMACEUTICALS, INC. (US) 2020-03-03 — — US disclosed
US-20190169122-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA PELLFICURE PHARMACEUTICALS 2019-06-06 — — US disclosed
US-20170283374-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA PELLFICURE PHARMACEUTICALS, INC. 2017-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190169122-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA KLK3, ACP3, NR5A1 MAPT 2538/4885ALDH1A1 314/4885LMNA 861/4885
US-20170283374-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA KLK3, ACP3, NR5A1 MAPT 2538/4885ALDH1A1 314/4885LMNA 861/4885
US-10577315-B2 Compositions and methods for treatment of prostate carcinoma KLK3, ACP3, NR5A1 MAPT 2538/4885ALDH1A1 314/4885LMNA 861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback